Zotarolimus-eluting stent utilization in small-vessel coronary artery disease (ZEUS) |
| |
Authors: | Man-Hong Jim Kai-Hang Yiu Raymond Chi-yan Fung Hee-Hwa Ho Andrew Kei-Yan Ng Chung-Wah Siu Wing-Hing Chow |
| |
Affiliation: | 1. Cardiac Medical Unit, Grantham Hospital, 125 Wong Chuk Hang Road, Hong Kong, Hong Kong 2. Division of Cardiology, Queen Mary Hospital, Hong Kong, Hong Kong 3. Department of Cardiology, Tan Tock Seng Hospital, Singapore, Singapore
|
| |
Abstract: | The role of the second-generation zotarolimus-eluting stent RESOLUTE in small-vessel coronary artery disease is unclear. The aim of this study was examine the angiographic results of RESOLUTE in de novo coronary lesions of ≥50 % diameter stenosis in target vessels ≤2.5 mm. From August 2008 to April 2010, 142 symptomatic patients with 159 lesions who fitted the inclusion criteria were treated with RESOLUTE. The mean age of patients was 66 ± 10 years, with male predominance (66 %). Diabetes mellitus was found in 62 (43.7 %) patients, whereas multivessel disease was observed in 105 (73.9 %). The mean stent size and length used were 2.33 ± 0.13 and 22 ± 8 mm, respectively. Follow-up angiography was performed on 143 (89.9 %) lesions in 127 (89.4 %) patients at a mean of 10.3 ± 3.6 months. Angiographic restenosis was found in 9 (6.3 %) lesions; the late loss was 0.26 ± 0.34 mm. At 1-year follow-up there were four cardiovascular deaths, two nonfatal myocardial infarctions, and six repeated revascularizations. The resultant major adverse cardiac event rate was 8.5 %. The use of RESOLUTE to treat small-vessel disease is associated with good clinical and angiographic outcomes at 1 year. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|